Hot October CPI Report Sends Stocks Lower as Markets Price In Another Fed Hike
Hotter October inflation pushed US stocks lower, lifted Treasury yields and the dollar, and strengthened expectations for another December Fed rate hi…
IsoEnergy Raises Premier American Uranium Stake to 22% as Sector Consolidation Continues
IsoEnergy’s move to raise its Premier American Uranium stake to 22% highlights consolidation and strategic positioning across North American uranium.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
GFL Environmental Shares Slide After Board Rejects C$52 Buyout Offer
GFL Environmental ended its strategic review without a sale after rejecting a $52-per-share private-equity offer, removi…
AstraZeneca’s Omniose Acquisition Signals Continued Appetite for Preclinical Biotech Deals
AstraZeneca’s acquisition of Omniose highlights its pipeline-building strategy and the pharmaceutical sector’s continued…
Zura Bio Plunges 76% After Tibulizumab Fails Phase 2 Hidradenitis Trial
Zura Bio shares plunged 76% after tibulizumab failed a Phase 2 hidradenitis trial, prompting the company to discontinue …
Vir Biotechnology’s Positive Phase 3 Hepatitis Delta Data Put $VIR in Focus
Vir Biotechnology’s positive Phase 3 ECLIPSE 1 readout may strengthen its regulatory outlook, but approval and valuation…
Eli Lilly’s Foundayo Sleep Apnea Results Set Up 2026 FDA Filing
Positive late-stage sleep apnea data could broaden Eli Lilly’s Foundayo franchise beyond weight management, with a U.S. …
RBC Initiates Eupraxia Coverage With Outperform Rating as Analysts Cite EP-104GI Data
RBC begins coverage of Eupraxia with an Outperform rating as analysts point to positive Phase 2b EP-104GI data and renew…
Genmab Shares Rise 4% After FDA Approves Partnered Cancer Drug
Genmab shares rose 4% after FDA approval of a Johnson & Johnson-partnered cancer drug, sharpening focus on its oncology …
Novocure Shares Slide After FDA Rejects Optune Mya Brain Metastases Application
Novocure shares were reported lower after the FDA issued a Not Approvable Letter for Optune Mya, clouding the company’s …
Phio Pharmaceuticals Moves PH-762 Toward Phase 2b After Q3 Update
Phio Pharmaceuticals is preparing PH-762 for a potential Phase 2b study as FDA discussions become the next key test for …